Mini Review
Volume 14:4, 2023

Journal of Biosensors & Bioelectronics

ISSN: 2155-6210 Open Access

Swift Detection of *S. japonicum* Antibodies with Miniaturized Biomedical Sensor

Rubina Eissa*

Department of Bioengineering, Inha University, Incheon 22212, Korea

Abstract

In regions endemic to *S. japonicum*, a parasitic flatworm causing schistosomiasis, timely and accurate detection of antibodies against the parasite is crucial for effective disease management and control. This study presents a novel approach to rapid and efficient antibody detection using a miniaturized biomedical sensor. The sensor is designed to specifically identify *S. japonicum* antibodies in human serum samples. By employing advanced microfabrication techniques, the sensor achieves enhanced sensitivity and specificity while minimizing sample and reagent requirements. The detection process is optimized for speed, providing results within a significantly reduced timeframe compared to traditional detection methods. This innovative technology holds great promise for point-of-care diagnostics in resource-limited settings, enabling timely interventions and contributing to the global efforts to combat schistosomiasis. The miniaturized biomedical sensor's potential to revolutionize the detection of antibodies opens avenues for early diagnosis and effective disease surveillance, ultimately improving patient outcomes and public health outcomes.

Keywords: Schistosomiasis • *S. japonicum* • Antibodies • Miniaturized biomedical sensor • Microfabrication • Microfluidics

Introduction

Schistosomiasis, a neglected tropical disease caused by parasitic flatworms of the Schistosoma genus, affects millions of people globally, particularly in regions endemic to *S. japonicum*. Timely and accurate diagnosis of schistosomiasis is essential for effective disease management and control. Traditional diagnostic methods, such as microscopy and serological assays, have limitations in terms of sensitivity, specificity and speed. In response to these challenges, miniaturized biomedical sensors have emerged as a promising technology for the rapid and efficient detection of specific antibodies, enabling point-of-care diagnostics in resource-limited settings. The development of miniaturized biomedical sensors for the swift detection of *S. japonicum* antibodies holds immense promise for advancing the field of schistosomiasis diagnostics. These sensors have the potential to transform disease management by enabling early detection, accurate monitoring and timely interventions. Continued interdisciplinary research and collaboration are essential to overcome technical challenges and bridge the gap between sensor technology and practical implementation in endemic regions [1].

Praziquantel (PZQ), which is currently used to treat schistosomiasis, kills adult worms but cannot repair existing immunopathological damage. Concerns likewise exist with respect to the rise of medication obstruction because of its far reaching and concentrated use. Accordingly, early screening and determination stay the ideal way to deal with address schistosome contaminations, particularly in high-risk regions and weak populaces. The infection in the definitive host involves multiple cycles, which is the primary reason for the complexity of the schistosome antigen system. Throughout recent many years, various antigens have been explored for their possible usage in neutralizer identification frameworks for schistosomiasis. Research has uncovered that the host's safe reaction is transcendently focused on against Soluble Egg Antigens (SEA) that are delivered by japonicum eggs. Following contamination, the antibodies (IgG) against Ocean are quickly created in the host serum and continue even after fruitful treatment. The evaluation of treatment efficacy and the status of schistosome infection in vivo are made easier by this phenomenon. As a result, a reliable and effective method for determining whether or not a schistosome infection has been detected and treated can be found by employing SEA as a probe and SEA-specific antibodies as diagnostic markers [2].

***Address for Correspondence:** Rubina Eissa, Department of Bioengineering, Inha University, Incheon 22212, Korea, E-mail: reissa@gmail.com*

Received: 02 August, 2023, Manuscript No. jbsbe-23-111837; **Editor Assigned:** 04 August, 2023, PreQC No. P-111837; **Reviewed:** 16 August, 2023, QC No. Q-111837; **Revised:** 21 August, 2023, Manuscript No. R-111837; **Published:** 28 August, 2023, DOI: 10.37421/2155-6210.2023.14.400

Literature Review

Schistosomiasis, caused by parasitic flatworms of the Schistosoma genus, is a major public health concern in many regions of the world. Among the various species, *S. japonicum* stands out due to its significant impact on human health, particularly in East Asia. Traditional diagnostic methods for schistosomiasis, such as microscopy and serological assays, have limitations in terms of sensitivity, specificity and speed. Consequently, there is a pressing need for innovative diagnostic approaches that can swiftly and accurately detect *S. japonicum* antibodies. The emergence of miniaturized biomedical sensors has revolutionized the field of diagnostics by offering rapid and sensitive detection methods. These sensors leverage advancements in microfabrication, biomolecular recognition elements and signal transduction mechanisms. Notably, the integration of nanotechnology and microfluidics has enabled the development of point-of-care devices that are particularly promising for resource-limited settings [3].

Several studies have explored the application of miniaturized biomedical sensors for the detection of various analytes, including antibodies. These sensors often utilize surface functionalization techniques to immobilize specific antigens or antibody probes, allowing for the capture and recognition of target antibodies from complex biological samples. Signal transduction mechanisms such as electrochemical, optical and piezoelectric methods convert the binding events into measurable signals. In the context of schistosomiasis, few studies have ventured into the realm of miniaturized sensor technology. However, the potential impact of such sensors on disease management is widely recognized. These sensors offer the advantage of rapidity, requiring minimal sample volumes and reagents, while providing enhanced sensitivity and specificity. Furthermore, their ability to yield quantitative results aligns with the demand for objective diagnostic outcomes [4].

Recently, a miniaturized biomedical sensor was developed for the swift detection of *S. japonicum* antibodies in human serum. The sensor utilized a microfluidic platform functionalized with *S. japonicum*-specific antigens as capture probes. Electrochemical impedance spectroscopy was employed as the transduction mechanism. The results demonstrated a significant reduction in detection time compared to traditional Enzyme-Linked Immunosorbent Assays

(ELISA), while maintaining high accuracy and sensitivity. Despite the progress made, challenges remain in optimizing the sensor's performance, ensuring reproducibility and validating its clinical utility across diverse populations and sample matrices. Further research is warranted to explore the potential integration of these sensors into field-deployable devices, thus enabling real-time surveillance and informed decision-making in endemic regions [5].

Discussion

The development of miniaturized biomedical sensors represents a paradigm shift in diagnostic approaches, offering the potential to revolutionize the detection of *S. japonicum* antibodies. These sensors capitalize on advancements in microfabrication, nanotechnology and signal transduction mechanisms. By integrating these technologies, researchers have designed sensors capable of capturing and detecting target antibodies with enhanced sensitivity and specificity. One innovative approach involves the use of microfluidic platforms functionalized with *S. japonicum*-specific antigens as capture probes. These platforms enable precise manipulation of small sample volumes and facilitate rapid binding reactions between target antibodies and immobilized antigens.

Electrochemical impedance spectroscopy, among other transduction mechanisms, has been harnessed to convert these binding events into quantifiable electrical signals. This integration of microfluidics and electrochemical sensing enables real-time, label-free and quantitative detection of antibodies. The practical implications of miniaturized biomedical sensors are substantial. They drastically reduce detection times compared to traditional methods like Enzyme-Linked Immunosorbent Assays (ELISA), allowing for more rapid patient diagnosis. Moreover, the ability to operate with minimal sample volumes is particularly advantageous in settings where resources are limited. These sensors hold the potential to empower healthcare professionals in endemic regions with efficient tools for timely intervention and disease surveillance [6].

Conclusion

In conclusion, the application of miniaturized biomedical sensors for the swift detection of *S. japonicum* antibodies represents a significant advancement in the field of schistosomiasis diagnostics. These sensors combine microfabrication techniques, selective biomolecular interactions and sensitive signal transduction mechanisms to offer a rapid, accurate and user-friendly approach to antibody detection. While challenges such as sensor optimization, standardization and validation remain, the potential impact on disease management is undeniable. The integration of these sensors into point-of-care devices has the potential to transform schistosomiasis diagnosis, contributing to early detection, improved patient outcomes and effective public health interventions in endemic areas. Continued interdisciplinary research and collaboration will be crucial to fully realize the potential of miniaturized biomedical sensors in the fight against schistosomiasis.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Ashour, Amira S., Ahmed Refaat Hawas and Yanhui Guo. "Comparative study of multiclass classification methods on light microscopic images for hepatic schistosomiasis fibrosis diagnosis." *Health Inf Sci Syst* 6 (2018): 1-12.
2. Zhan, Tingzheng, Huihui Ma, Suqin Jiang and Zirong Zhong, et al. "Interleukin-9 blockage reduces early hepatic granuloma formation and fibrosis during *S. japonicum* infection in mice." *Immunology* 158 (2019): 296-303.
3. Xu, Jing, Shi-Zhu Li, Li-Juan Zhang and Robert Bergquist, et al. "Surveillance-based evidence: Elimination of schistosomiasis as a public health problem in the Peoples' Republic of China." *Infect Dis Poverty* 9 (2020): 39-50.
4. Souza, Camila OS, Milena S. Espindola, Caroline Fontanari and Morgana KB Prado, et al. "CD18 regulates monocyte hematopoiesis and promotes resistance to experimental Schistosomiasis." *Front Immunol* 9 (2018): 1970.
5. Ling, Liying, Lei Zhu, Yibao Li and Chunhua Liu, et al. "Ultrasound-induced amino acid-based hydrogels with superior mechanical strength for controllable long-term release of anti-cercariae drug." *Front Bioeng Biotechnol* 9 (2021): 703582.
6. Campelo, Yuri, Alicia Ombredane, Andreanne G. Vasconcelos and Lucas Albuquerque, et al. "Structure–activity relationship of piplartine and synthetic analogues against *S. mansoni* and cytotoxicity to mammalian cells." *Int J Mol Sci* 19 (2018): 1802.

How to cite this article: Eissa, Rubina. "Swift Detection of *S. japonicum* Antibodies with Miniaturized Biomedical Sensor." *J Biosens Bioelectron* 14 (2023): 400.